| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $49,936,340 ) (Continued on the next page) |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U01CA274971 | Advancing Clinical Trials: Working through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDERS) | 002 | 3 | NIH | 9/4/2024 | $0 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U01CA274971 | Advancing Clinical Trials: Working through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDERS) | 001 | 3 | NIH | 8/20/2024 | $706,600 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA262483 | Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma | 000 | 3 | NIH | 7/9/2024 | $463,483 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA263575 | Novel Therapy to Inhibit IPMN Progression | 000 | 3 | NIH | 6/10/2024 | $635,784 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R37CA266727 | Characterizing cytotoxic therapy induced shifts in the cost-to-benefit ratio of high ploidy | 000 | 3 | NIH | 8/21/2024 | $480,392 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U01CA274489 | Analytical tools for studying the tumor microenvironment leveraging spatial transcriptomics | 002 | 3 | NIH | 8/15/2024 | $397,545 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA272601 | Modeling the role and regulation of reactive stroma in breast ductal carcinoma microinvasions | 000 | 3 | NIH | 8/15/2024 | $551,254 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA244328 | Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison | 001 | 3 | NIH | 8/7/2024 | $160,118 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01DA055298 | Augmented Reality as an Adjunct to Quitline Counseling for Smoking Cessation | 000 | 3 | NIH | 5/22/2024 | $725,126 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA273034 | Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors | 000 | 3 | NIH | 7/23/2024 | $366,172 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | K22CA262352 | Tele-resistance training during chemotherapy for advanced upper gastrointestinal cancer | 000 | 3 | NIH | 2/14/2024 | $161,973 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U24CA284167 | Developing a Cancer Galaxy Computational Workbench to Meet Emerging Cancer Data Analysis Needs | 000 | 1 | NIH | 8/16/2024 | $877,856 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA268973 | HIV Genomic Aging Project in Oncology (HIV-GAP) | 000 | 4 | NIH | 8/2/2024 | $761,817 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01NS117926 | Elucidating the epigenetic landscape of neurofibromatosis and development of therapeutic targets | 000 | 4 | NIH | 8/20/2024 | $395,445 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA256193 | Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis | 000 | 4 | NIH | 8/16/2024 | $618,592 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | DP2AG077698 | AGING AS A SELECTIVE PRESSURE THAT DRIVES TUMOR PROGRESSION | 000 | 2 | NIH | 8/9/2024 | $990,450 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM143004 | Biophysical basis for enzyme mediated deglycation in protein repair | 001 | 4 | NIH | 7/31/2024 | $41,175 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM143004 | Biophysical basis for enzyme mediated deglycation in protein repair | 000 | 4 | NIH | 2/27/2024 | $370,575 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA262121 | Bile acids restrict functional reprogramming of myeloid-derived suppressor cells in tumor beds | 000 | 4 | NIH | 7/25/2024 | $357,915 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA259046 | Chromosome 1q ceRNAs in Melanoma Progression and Metastasis | 000 | 4 | NIH | 5/8/2024 | $396,092 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA249016 | Radiomics and Pathomics to predict upstaging of DCIS | 000 | 4 | NIH | 7/2/2024 | $648,573 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA260356 | Anti-tumor potential of temperature-sensitive p53 mutants | 001 | 4 | NIH | 4/17/2024 | $22,230 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA260356 | Anti-tumor potential of temperature-sensitive p53 mutants | 000 | 4 | NIH | 2/9/2024 | $400,130 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA258089 | Eco-evolutionary drivers of clonal dynamics during UV-induced skin carcinogenesis (PQ3) | 001 | 4 | NIH | 4/17/2024 | $32,002 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA258089 | Eco-evolutionary drivers of clonal dynamics during UV-induced skin carcinogenesis (PQ3) | 000 | 4 | NIH | 3/6/2024 | $576,018 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA259387 | Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer | 001 | 4 | NIH | 4/18/2024 | $23,802 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA259387 | Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer | 000 | 4 | NIH | 3/11/2024 | $428,435 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01GM140140 | Direct Control of the human CMG Helicase by Myc and Rb | 000 | 4 | NIH | 5/15/2024 | $329,400 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM142577 | New reagents for C-C and C-N bond formation | 001 | 4 | NIH | 8/2/2024 | $41,175 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM142577 | New reagents for C-C and C-N bond formation | 000 | 4 | NIH | 4/15/2024 | $370,575 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01DE030123 | Role of CRTC1-MAML2 in Salivary Mucoepidermoid Carcinoma Pathobiology | 001 | 5 | NIH | 6/14/2024 | $40,163 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01DE030123 | Role of CRTC1-MAML2 in Salivary Mucoepidermoid Carcinoma Pathobiology | 000 | 5 | NIH | 4/2/2024 | $451,837 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | P01CA250984 | Identifying Metabolic Vulnerabilities in Lung Cancer | 000 | 4 | NIH | 7/1/2024 | $1,951,918 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA262530 | Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers | 000 | 4 | NIH | 7/3/2024 | $649,046 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U01CA244101 | Defining bone ecosystem effects on metastatic prostate cancer evolution and treatment response using an integrated mathematical modeling approach | 000 | 5 | NIH | 5/22/2024 | $442,936 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01DK125367 | Improving weight loss outcomes of black women using a culturally relevant, stress management enhancement behavioral weight loss intervention | 000 | 5 | NIH | 5/8/2024 | $596,832 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA241713 | New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma | 000 | 5 | NIH | 6/3/2024 | $526,993 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA249689 | CARES-REACH (Colorectal Cancer Awareness, Research, Education and Screening-Rural Expansion, Access and Capacity for Health) | 001 | 5 | NIH | 4/18/2024 | $31,626 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA249689 | CARES-REACH (Colorectal Cancer Awareness, Research, Education and Screening-Rural Expansion, Access and Capacity for Health) | 000 | 5 | NIH | 2/19/2024 | $569,287 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA278300 | The impact of inflammation on HSPC composition and disease progression in chronic myelomonocytic leukemia | 001 | 2 | NIH | 4/17/2024 | $29,863 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA278300 | The impact of inflammation on HSPC composition and disease progression in chronic myelomonocytic leukemia | 000 | 2 | NIH | 2/15/2024 | $537,519 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA242742 | Identifying and Reducing Disparities in Patient-Reported Outcomes Among African American Prostate Cancer Survivors | 000 | 5 | NIH | 5/29/2024 | $356,298 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA239219 | Imaging Acidosis and Immune Therapy in PDAC | 001 | 5 | NIH | 4/17/2024 | $34,175 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA239219 | Imaging Acidosis and Immune Therapy in PDAC | 000 | 5 | NIH | 1/31/2024 | $615,154 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA243552 | Randomized Trial of Automated Video-Assisted Smoking Treatment for People Living with HIV | 000 | 6 | NIH | 8/13/2024 | $454,228 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | K08CA252642 | Leveraging the Lymphocytic Infiltration of Soft Tissue Sarcoma for Autologous Cellular Immunotherapy | 000 | 5 | NIH | 7/17/2024 | $245,296 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R37CA234021 | Developing and credentialing patient-derived xenograft models to advance therapeutic approaches for chronic myelomonocytic leukemia | 000 | 6 | NIH | 8/29/2024 | $453,813 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA250514 | Study of Anti-Tumor Immunity and Tissue Resident Memory Cell Development by NKG2D and Ribosomal Protein S6 Signaling in T cells | 001 | 6 | NIH | 4/17/2024 | $18,839 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA250514 | Study of Anti-Tumor Immunity and Tissue Resident Memory Cell Development by NKG2D and Ribosomal Protein S6 Signaling in T cells | 000 | 6 | NIH | 2/8/2024 | $339,076 |
|
